STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 98 filers reported holding STEMLINE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 2.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $545,000 | -92.5% | 42,396 | -94.4% | 1.68% | -77.0% |
| Q4 2018 | $7,248,000 | -69.9% | 762,941 | -47.4% | 7.29% | -51.4% |
| Q3 2018 | $24,098,000 | +2.0% | 1,451,700 | -1.3% | 15.01% | +78.7% |
| Q2 2018 | $23,618,000 | +24.4% | 1,471,518 | +18.5% | 8.40% | +37.3% |
| Q1 2018 | $18,992,000 | +46.8% | 1,241,293 | +49.7% | 6.12% | +41.8% |
| Q4 2017 | $12,934,000 | +115.2% | 829,090 | +53.1% | 4.31% | +86.1% |
| Q3 2017 | $6,010,000 | +420.3% | 541,462 | +331.1% | 2.32% | +398.3% |
| Q2 2017 | $1,155,000 | – | 125,595 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
| Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
| NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
| Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
| Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
| KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
| Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
| Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
| J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |